Phase II trial of 4'-epidoxorubicin in advanced gastrointestinal tumor.
Fourteen Chinese patients with histologically proven advanced gastrointestinal tumors underwent a phase II 4'-epidoxorubicin trial. 6 out of 14 (42%) patients showed static response and the rest showed progression of disease during treatment. The treatment was fairly well tolerated with a mild to moderate degree of nausea, vomiting, alopecia and hematological toxicity.
Shiu
W
W
O
S K
SK
Tsao
S Y
SY
Woo
K S
KS
Martin
C
C
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D015251:Epirubicin; D004317:Doxorubicin